NCT01221675View on ClinicalTrials.gov

TF2- Small Cell Lung Cancer Radio Immunotherapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Small Cell Lung CancerCEA-expressing Non Small Cell Lung Carcinoma (NSCLC)
Interventions
DRUG

Antibody TF2

preciblage with an antibody

RADIATION

IMP-288-Lutetium

Internal Radiation

RADIATION

IMP-288-Indium

Imaging

Trial Locations (6)

29000

CHU, Brest

38000

Hôpital La tronche, Grenoble

44093

Hotel Dieu, Nantes

44805

Centre René Gauducheau, Saint-Herblain

49100

CHU d'Angers, Angers

Unknown

Centre Jean Perrin, Clermont-Ferrand

All Listed Sponsors
lead

Centre René Gauducheau

OTHER

NCT01221675 - TF2- Small Cell Lung Cancer Radio Immunotherapy | Biotech Hunter | Biotech Hunter